Innovation “Crisis” And Health Care Reform: Lilly CEO Urges Change In Focus
This article was originally published in The Pink Sheet Daily
Executive Summary
Lechleiter editorial, Chamber of Commerce appearance include warnings about adverse effects on innovation; “Odyssey Project” launched to press similar themes.
You may also be interested in...
Pharma Share Of Health Reform Cost Savings To Come From Drug Access, Compliance, Personalized Medicine
As stakeholders pledge to reduce health system growth by $2 trillion over 10 years, Rep. Dingell urges support for public plan; Sen. Grassley wants more “concrete” proposals, CBO score.
NASH Accelerated Approval: US FDA Remains Confident In Pathway For Liver Disease
A two-day workshop on potential biomarkers in NASH provided a forum for US FDA officials to offer implicit reassurance to drug developers: the agency stands behind its guidance on Accelerated Approval for the liver disease, despite the rejection of the first application seeking to use that approach.
Yet Another Bad Day For PBMs On Capitol Hill
Democrats and Republicans in the US Congress are not getting along on most topics these days. But when it comes to criticizing the pharmacy benefit management sector, they see eye-to-eye.